Get Details

Zachariah McIver, D.O., Ph.D.

Vice President, Clinical Development

An accomplished physician-scientist with over 15-years of experience in clinical research, Dr. Zachariah McIver joins Janux after serving as Amgen’s Executive Medical Director for over 4 years, leading cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies. During his time at Amgen, Dr. McIver led the efforts in maximizing the value of bispecific T-cell engager (BiTE) assets across multiple hematologic and solid tumor malignancies.

A board-certified hematologist and physician-scientist, he began his career specializing in hematological malignancies and immunotherapy working as a principal investigator at the Hematology Branch of the NHLBI at the NIH. Dr. McIver has also played a key role in developing novel small molecules targeting alloreactive T-cells to prevent graft-versus-host-disease (GVHD) and established a stem cell transplant program for racial minority populations at the Wake Forest School of Medicine in Winston-Salem, NC. He also served as an attending physician at Wake Forest in the hematology/oncology department. Prior to this, Dr. McIver was an attending physician and a research investigator in the department of hematology/oncology at Tulane University School of Medicine.

Dr. McIver earned a B.S. in Physics and General Sciences from the University of Oregon, a Medical Doctorate (DO) from Ohio University College of Osteopathic Medicine and a PhD in Molecular Medicine and Translational Sciences at the Wake Forest University School of Medicine. He completed his internal medicine residency at the Cleveland Clinic, and his clinical fellowship in hematology and oncology at the National Heart, Lung, and Blood Institute (NHLBI) at the NIH. In addition, Dr. McIver is an active member of professional societies such as the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and American College of Physicians (ACP).

Let’s do some great work together to bring game-changing medicines to patients.